Cipla and Qilu Pharmaceutical secure US biosimilar rights for Keytruda

The Indian drugmaker partnered with a Chinese rival to license and distribute a pembrolizumab biosimilar, expanding its footprint in the lucrative oncology market.

3 Sept, 16:23 — 3 Sept, 16:23

Post Share

Sources

Showing 1 of 1 sources

morningstar1d ago

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US - Morningstar

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US Morningstar

Read full article →

Cipla and Qilu Pharmaceutical secure US biosimilar rights for Keytruda

Sources

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US - Morningstar

Related Stories

US Signs Controversial Oil Deal with Venezuela Amid Geopolitical Shifts

US Gasoline Prices Hit Record Highs During Labor Day Weekend

UN Report Shows Global Food Prices Reach Highest Level Since 2022

Indian Agency Books Zee Founder in Major Banking Fraud Case